Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MicroPort®

MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

DISCLOSEABLE TRANSACTION

DECONSOLIDATION

Reference is made the announcement dated 29 December of 2025 of MicroPort NeuroScientific Corporation (the "**Target Company**") regarding the appointment of an independent non-executive director to its board. Prior to the appointment, the Company controlled the board of the Target Company. With the appointment, the Company has assessed the shift in the balance on the Target Company's board in the context of the shareholdings in the Target Company held by the Company and other shareholders. The Company concluded that it would not control the Target Company in accordance with the Group's accounting policies but would retain significant influence over the Target Company, and that it would be appropriate to deconsolidate the Target Company. The deconsolidation of the Target Company constitutes a discloseable transaction of the Company under the Listing Rules.

INFORMATION OF THE PARTIES

The Company

The Company is incorporated in the Cayman Islands and its shares are listed on the Main Board of the Stock Exchange. The Company, together with its subsidiaries, is a leading medical device group focusing on innovating, manufacturing and marketing high-end medical devices globally in a broad range of business segments including cardiovascular devices, orthopedics devices, endovascular and peripheral vascular devices, structural heart intervention and cardiac rhythm management, surgical robot and other businesses.

The Target Company

The Target Company is incorporated in the Cayman Islands and its shares are listed on the Main Board of the Stock Exchange (Stock Code: 02172). The Target Company, together with its subsidiaries, is principally engaged in the research and development, manufacture and sale of innovative neuro-interventional medical devices.

FINANCIAL INFORMATION OF THE TARGET COMPANY

Set out below are the key financial figures of the Target Company for the two years ended 31 December 2024 and the six months ended 30 June 2025:

	For the year ended 31 December		For the six months ended 30 June
	2023	**2024**	**2025**
	(audited)	**(audited)**	**(unaudited)**
	(RMB'000)	*(RMB'000)*	*(RMB'000)*
Net profit before taxation	162,051	302,733	113,569
Net profit after taxation	134,581	248,855	92,734

The net assets of the Target Company as at 30 June 2025 was approximately RMB1,724,646,000.

FINANCIAL IMPACT

The deconsolidation of the Target Company is expected to result in a deemed gain on disposal of subsidiaries recognised in the consolidated financial statements of the Company. The relevant gain will be calculated with reference to, among others, the fair value of the equity interest held by the Company in the Target Company, the net asset value of the Target Company as at the date of the loss of control. The actual amount of gain to be recorded by the Group will be subject to review and final audit by the auditor of the Company.

DEFINITIONS

In this announcement, the following expressions shall have the following meanings unless the context requires otherwise:

"Board"	the board of the Company
"Company"	MicroPort Scientific Corporation, a company incorporated in the Cayman Islands with limited liability, the shares of which are listed on the Main Board of the Stock Exchange (Stock Code: 00853)
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
"Stock Exchange"	The Stock Exchange of Hong Kong Limited

By order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 30 December 2025

As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Dr. Feng Gu, Dr. Qingbing Men and Ms. Weiqin Sun; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* *For identification purpose only.*